Search

Your search keyword '"Pintilie, Melania"' showing total 1,050 results
Start Over Author "Pintilie, Melania"
1,050 results on '"Pintilie, Melania"'

4. Competing Risk Models

Author

Pintilie, Melania, Sobolev, Boris, Series Editor, Levy, Adrian, editor, Goring, Sarah, editor, Gatsonis, Constantine, editor, van Ginneken, Ewout, editor, and Busse, Reinhard, editor

Published
2019
Full Text
View/download PDF

6. Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers

Author

Pham, Nhu-An, Radulovich, Nikolina, Ibrahimov, Emin, Martins-Filho, Sebastiao N., Li, Quan, Pintilie, Melania, Weiss, Jessica, Raghavan, Vibha, Cabanero, Michael, Denroche, Robert E., Wilson, Julie M., Metran-Nascente, Cristiane, Borgida, Ayelet, Hutchinson, Shawn, Dodd, Anna, Begora, Michael, Chadwick, Dianne, Serra, Stefano, Knox, Jennifer J., Gallinger, Steven, Hedley, David W., Muthuswamy, Lakshmi, and Tsao, Ming-Sound

Published
2021
Full Text
View/download PDF

8. Developing a prognostic micro-RNA signature for human cervical carcinoma.

Author

How, Christine, Pintilie, Melania, Bruce, Jeff P, Hui, Angela BY, Clarke, Blaise A, Wong, Philip, Yin, Shaoming, Yan, Rui, Waggott, Daryl, Boutros, Paul C, Fyles, Anthony, Hedley, David W, Hill, Richard P, Milosevic, Michael, and Liu, Fei-Fei

Subjects
Humans, MicroRNAs, Prognosis, Disease-Free Survival, Paraffin Embedding, Reproducibility of Results, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Adult, Aged, Aged, 80 and over, Middle Aged, Uterine Cervical Neoplasms, Female, Young Adult, and over, Gene Expression Regulation, Neoplastic, General Science & Technology
Abstract

Cervical cancer remains the third most frequently diagnosed and fourth leading cause of cancer death in women worldwide. We sought to develop a micro-RNA signature that was prognostic for disease-free survival, which could potentially allow tailoring of treatment for cervical cancer patients. A candidate prognostic 9-micro-RNA signature set was identified in the training set of 79 frozen specimens. However, three different approaches to validate this signature in an independent cohort of 87 patients with formalin-fixed paraffin-embedded (FFPE) specimens, were unsuccessful. There are several challenges and considerations associated with developing a prognostic micro-RNA signature for cervical cancer, namely: tumour heterogeneity, lack of concordance between frozen and FFPE specimens, and platform selection for global micro-RNA expression profiling in this disease. Our observations provide an important cautionary tale for future miRNA signature studies for cervical cancer, which can also be potentially applicable to miRNA profiling studies involving other types of human malignancies.

Published
2015

12. Characterization of Distinct Populations of Carcinoma-Associated Fibroblasts from Non–Small Cell Lung Carcinoma Reveals a Role for ST8SIA2 in Cancer Cell Invasion

Author

Hao, Jing, Zeltz, Cédric, Pintilie, Melania, Li, Quan, Sakashita, Shingo, Wang, Tao, Cabanero, Michael, Martins-Filho, Sebastiao N., Wang, Dennis Y., Pasko, Elena, Venkat, Kalpana, Joseph, Joella, Raghavan, Vibha, Zhu, Chang-Qi, Wang, Yu-Hui, Moghal, Nadeem, Tsao, Ming-Sound, and Navab, Roya

Published
2019
Full Text
View/download PDF

16. MicroRNA-196b regulates the homeobox B7-vascular endothelial growth factor axis in cervical cancer.

Author

How, Christine, Hui, Angela BY, Alajez, Nehad M, Shi, Wei, Boutros, Paul C, Clarke, Blaise A, Yan, Rui, Pintilie, Melania, Fyles, Anthony, Hedley, David W, Hill, Richard P, Milosevic, Michael, and Liu, Fei-Fei

Subjects
Cell Line, Tumor, Humans, Carcinoma, Squamous Cell, Vascular Endothelial Growth Factor A, Homeodomain Proteins, MicroRNAs, RNA, Small Interfering, RNA, Messenger, Antineoplastic Agents, Survival Analysis, Signal Transduction, Cell Proliferation, Transcription, Genetic, Gene Expression Regulation, Neoplastic, Gamma Rays, Adult, Aged, Aged, 80 and over, Middle Aged, Uterine Cervical Neoplasms, Female, and over, Carcinoma, Squamous Cell, Cell Line, Tumor, Gene Expression Regulation, Neoplastic, RNA, Messenger, Small Interfering, Transcription, Genetic, General Science & Technology
Abstract

The down-regulation of microRNA-196b (miR-196b) has been reported, but its contribution to cervical cancer progression remains to be investigated. In this study, we first demonstrated that miR-196b down-regulation was significantly associated with worse disease-free survival (DFS) for cervical cancer patients treated with combined chemo-radiation. Secondly, using a tri-modal approach for target identification, we determined that homeobox-B7 (HOXB7) was a bona fide target for miR-196b, and in turn, vascular endothelial growth factor (VEGF) was a downstream transcript regulated by HOXB7. Reconstitution of miR-196b expression by transient transfection resulted in reduced cell growth, clonogenicity, migration and invasion in vitro, as well as reduced tumor angiogenesis and tumor cell proliferation in vivo. Concordantly, siRNA knockdown of HOXB7 or VEGF phenocopied the biological effects of miR-196b over-expression. Our findings have demonstrated that the miR-196b/HOXB7/VEGF pathway plays an important role in cervical cancer progression; hence targeting this pathway could be a promising therapeutic strategy for the future management of this disease.

Published
2013

18. Exploiting the noise: improving biomarkers with ensembles of data analysis methodologies

Author

Starmans, Maud HW, Pintilie, Melania, John, Thomas, Der, Sandy D, Shepherd, Frances A, Jurisica, Igor, Lambin, Philippe, Tsao, Ming-Sound, and Boutros, Paul C

Subjects
Cancer, Clinical Research, Lung Cancer, Lung, 4.1 Discovery and preclinical testing of markers and technologies, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, Good Health and Well Being, Genetics, Clinical Sciences
Abstract

BackgroundThe advent of personalized medicine requires robust, reproducible biomarkers that indicate which treatment will maximize therapeutic benefit while minimizing side effects and costs. Numerous molecular signatures have been developed over the past decade to fill this need, but their validation and up-take into clinical settings has been poor. Here, we investigate the technical reasons underlying reported failures in biomarker validation for non-small cell lung cancer (NSCLC).MethodsWe evaluated two published prognostic multi-gene biomarkers for NSCLC in an independent 442-patient dataset. We then systematically assessed how technical factors influenced validation success.ResultsBoth biomarkers validated successfully (biomarker #1: hazard ratio (HR) 1.63, 95% confidence interval (CI) 1.21 to 2.19, P = 0.001; biomarker #2: HR 1.42, 95% CI 1.03 to 1.96, P = 0.030). Further, despite being underpowered for stage-specific analyses, both biomarkers successfully stratified stage II patients and biomarker #1 also stratified stage IB patients. We then systematically evaluated reasons for reported validation failures and find they can be directly attributed to technical challenges in data analysis. By examining 24 separate pre-processing techniques we show that minor alterations in pre-processing can change a successful prognostic biomarker (HR 1.85, 95% CI 1.37 to 2.50, P < 0.001) into one indistinguishable from random chance (HR 1.15, 95% CI 0.86 to 1.54, P = 0.348). Finally, we develop a new method, based on ensembles of analysis methodologies, to exploit this technical variability to improve biomarker robustness and to provide an independent confidence metric.ConclusionsBiomarkers comprise a fundamental component of personalized medicine. We first validated two NSCLC prognostic biomarkers in an independent patient cohort. Power analyses demonstrate that even this large, 442-patient cohort is under-powered for stage-specific analyses. We then use these results to discover an unexpected sensitivity of validation to subtle data analysis decisions. Finally, we develop a novel algorithmic approach to exploit this sensitivity to improve biomarker robustness.

Published
2012

27. A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer risk

Author

Koh, Eng-Siew, Tran, Tu Huan, Heydarian, Mostafa, Sachs, Rainer K, Tsang, Richard W, Brenner, David J, Pintilie, Melania, Xu, Tony, Chung, June, Paul, Narinder, and Hodgson, David C

Subjects
Lung, Cancer, Cardiovascular, Heart Disease, Rare Diseases, Lymphoma, Hematology, 6.5 Radiotherapy and other non-invasive therapies, Evaluation of treatments and therapeutic interventions, Adolescent, Adult, Female, Hodgkin Disease, Humans, Lung Neoplasms, Male, Mediastinum, Medical Oncology, Middle Aged, Neoplasm Metastasis, Neoplasms, Second Primary, Radiometry, Radiotherapy, Risk, Treatment Outcome, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundHodgkin's lymphoma (HL) survivors who undergo radiotherapy experience increased risks of second cancers (SC) and cardiac sequelae. To reduce such risks, extended-field radiotherapy (RT) for HL has largely been replaced by involved field radiotherapy (IFRT). While it has generally been assumed that IFRT will reduce SC risks, there are few data that quantify the reduction in dose to normal tissues associated with modern RT practice for patients with mediastinal HL, and no estimates of the expected reduction in SC risk.MethodsOrgan-specific dose-volume histograms (DVH) were generated for 41 patients receiving 35 Gy mantle RT, 35 Gy IFRT, or 20 Gy IFRT, and integrated organ mean doses were compared for the three protocols. Organ-specific SC risk estimates were estimated using a dosimetric risk-modeling approach, analyzing DVH data with quantitative, mechanistic models of radiation-induced cancer.ResultsDose reductions resulted in corresponding reductions in predicted excess relative risks (ERR) for SC induction. Moving from 35 Gy mantle RT to 35 Gy IFRT reduces predicted ERR for female breast and lung cancer by approximately 65%, and for male lung cancer by approximately 35%; moving from 35 Gy IFRT to 20 Gy IFRT reduces predicted ERRs approximately 40% more. The median reduction in integral dose to the whole heart with the transition to 35 Gy IFRT was 35%, with a smaller (2%) reduction in dose to proximal coronary arteries. There was no significant reduction in thyroid dose.ConclusionThe significant decreases estimated for radiation-induced SC risks associated with modern IFRT provide strong support for the use of IFRT to reduce the late effects of treatment. The approach employed here can provide new insight into the risks associated with contemporary IFRT for HL, and may facilitate the counseling of patients regarding the risks associated with this treatment.

Published
2007

30. Phase 1/2 Study of the Addition of Cisplatin to Adjuvant Chemotherapy With Image Guided High-Precision Radiation Therapy for Completely Resected Gastric Cancer

Author

Goody, Rebecca B., MacKay, Helen, Pitcher, Bethany, Oza, Amit, Siu, Lillian L., Kim, John, Wong, Rebecca K.S., Chen, Eric, Swallow, Carol, Knox, Jennifer, Kassam, Zahra, Cummings, Bernard, Feld, Ron, Hedley, David, Liu, Geoffrey, Krzyzanowska, Monika K., Dinniwell, Robert, Brade, Anthony M., Dawson, Laura A., Pintilie, Melania, and Ringash, Jolie

Published
2016
Full Text
View/download PDF

31. Supplementary Tables 1-5 from Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer

Author

Marastoni, Stefano, primary, Madariaga, Ainhoa, primary, Pesic, Aleksandra, primary, Nair, Sree Narayanan, primary, Li, Zhu Juan, primary, Shalev, Zvi, primary, Ketela, Troy, primary, Colombo, Ilaria, primary, Mandilaras, Victoria, primary, Cabanero, Michael, primary, Bruce, Jeff P., primary, Li, Xuan, primary, Garg, Swati, primary, Wang, Lisa, primary, Chen, Eric X., primary, Gill, Sarbjot, primary, Dhani, Neesha C., primary, Zhang, Wenjiang, primary, Pintilie, Melania, primary, Bowering, Valerie, primary, Koritzinsky, Marianne, primary, Rottapel, Robert, primary, Wouters, Bradly G., primary, Oza, Amit M., primary, Joshua, Anthony M., primary, and Lheureux, Stephanie, primary

Published
2023
Full Text
View/download PDF

32. Data from Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer

Author

Marastoni, Stefano, primary, Madariaga, Ainhoa, primary, Pesic, Aleksandra, primary, Nair, Sree Narayanan, primary, Li, Zhu Juan, primary, Shalev, Zvi, primary, Ketela, Troy, primary, Colombo, Ilaria, primary, Mandilaras, Victoria, primary, Cabanero, Michael, primary, Bruce, Jeff P., primary, Li, Xuan, primary, Garg, Swati, primary, Wang, Lisa, primary, Chen, Eric X., primary, Gill, Sarbjot, primary, Dhani, Neesha C., primary, Zhang, Wenjiang, primary, Pintilie, Melania, primary, Bowering, Valerie, primary, Koritzinsky, Marianne, primary, Rottapel, Robert, primary, Wouters, Bradly G., primary, Oza, Amit M., primary, Joshua, Anthony M., primary, and Lheureux, Stephanie, primary

Published
2023
Full Text
View/download PDF

33. Supplementary Materials and Methods from Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer

Author

Marastoni, Stefano, primary, Madariaga, Ainhoa, primary, Pesic, Aleksandra, primary, Nair, Sree Narayanan, primary, Li, Zhu Juan, primary, Shalev, Zvi, primary, Ketela, Troy, primary, Colombo, Ilaria, primary, Mandilaras, Victoria, primary, Cabanero, Michael, primary, Bruce, Jeff P., primary, Li, Xuan, primary, Garg, Swati, primary, Wang, Lisa, primary, Chen, Eric X., primary, Gill, Sarbjot, primary, Dhani, Neesha C., primary, Zhang, Wenjiang, primary, Pintilie, Melania, primary, Bowering, Valerie, primary, Koritzinsky, Marianne, primary, Rottapel, Robert, primary, Wouters, Bradly G., primary, Oza, Amit M., primary, Joshua, Anthony M., primary, and Lheureux, Stephanie, primary

Published
2023
Full Text
View/download PDF

34. Supplementary File 2 from Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer

Author

Marastoni, Stefano, primary, Madariaga, Ainhoa, primary, Pesic, Aleksandra, primary, Nair, Sree Narayanan, primary, Li, Zhu Juan, primary, Shalev, Zvi, primary, Ketela, Troy, primary, Colombo, Ilaria, primary, Mandilaras, Victoria, primary, Cabanero, Michael, primary, Bruce, Jeff P., primary, Li, Xuan, primary, Garg, Swati, primary, Wang, Lisa, primary, Chen, Eric X., primary, Gill, Sarbjot, primary, Dhani, Neesha C., primary, Zhang, Wenjiang, primary, Pintilie, Melania, primary, Bowering, Valerie, primary, Koritzinsky, Marianne, primary, Rottapel, Robert, primary, Wouters, Bradly G., primary, Oza, Amit M., primary, Joshua, Anthony M., primary, and Lheureux, Stephanie, primary

Published
2023
Full Text
View/download PDF

35. Supplementary File 1 from Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer

Author

Marastoni, Stefano, primary, Madariaga, Ainhoa, primary, Pesic, Aleksandra, primary, Nair, Sree Narayanan, primary, Li, Zhu Juan, primary, Shalev, Zvi, primary, Ketela, Troy, primary, Colombo, Ilaria, primary, Mandilaras, Victoria, primary, Cabanero, Michael, primary, Bruce, Jeff P., primary, Li, Xuan, primary, Garg, Swati, primary, Wang, Lisa, primary, Chen, Eric X., primary, Gill, Sarbjot, primary, Dhani, Neesha C., primary, Zhang, Wenjiang, primary, Pintilie, Melania, primary, Bowering, Valerie, primary, Koritzinsky, Marianne, primary, Rottapel, Robert, primary, Wouters, Bradly G., primary, Oza, Amit M., primary, Joshua, Anthony M., primary, and Lheureux, Stephanie, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Figures 1-7 from Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer

Author

Marastoni, Stefano, primary, Madariaga, Ainhoa, primary, Pesic, Aleksandra, primary, Nair, Sree Narayanan, primary, Li, Zhu Juan, primary, Shalev, Zvi, primary, Ketela, Troy, primary, Colombo, Ilaria, primary, Mandilaras, Victoria, primary, Cabanero, Michael, primary, Bruce, Jeff P., primary, Li, Xuan, primary, Garg, Swati, primary, Wang, Lisa, primary, Chen, Eric X., primary, Gill, Sarbjot, primary, Dhani, Neesha C., primary, Zhang, Wenjiang, primary, Pintilie, Melania, primary, Bowering, Valerie, primary, Koritzinsky, Marianne, primary, Rottapel, Robert, primary, Wouters, Bradly G., primary, Oza, Amit M., primary, Joshua, Anthony M., primary, and Lheureux, Stephanie, primary

Published
2023
Full Text
View/download PDF

37. Clinical Trial Protocol from Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer

Author

Marastoni, Stefano, primary, Madariaga, Ainhoa, primary, Pesic, Aleksandra, primary, Nair, Sree Narayanan, primary, Li, Zhu Juan, primary, Shalev, Zvi, primary, Ketela, Troy, primary, Colombo, Ilaria, primary, Mandilaras, Victoria, primary, Cabanero, Michael, primary, Bruce, Jeff P., primary, Li, Xuan, primary, Garg, Swati, primary, Wang, Lisa, primary, Chen, Eric X., primary, Gill, Sarbjot, primary, Dhani, Neesha C., primary, Zhang, Wenjiang, primary, Pintilie, Melania, primary, Bowering, Valerie, primary, Koritzinsky, Marianne, primary, Rottapel, Robert, primary, Wouters, Bradly G., primary, Oza, Amit M., primary, Joshua, Anthony M., primary, and Lheureux, Stephanie, primary

Published
2023
Full Text
View/download PDF

38. Supplementary Figure 2 from Mitochondrial Aconitase ACO2 Links Iron Homeostasis with Tumorigenicity in Non–Small Cell Lung Cancer

Author

Mirhadi, Shideh, primary, Zhang, Wen, primary, Pham, Nhu-An, primary, Karimzadeh, Fereshteh, primary, Pintilie, Melania, primary, Tong, Jiefei, primary, Taylor, Paul, primary, Krieger, Jonathan, primary, Pitcher, Bethany, primary, Sykes, Jenna, primary, Wybenga-Groot, Leanne, primary, Fladd, Christopher, primary, Xu, Jing, primary, Wang, Tao, primary, Cabanero, Michael, primary, Li, Ming, primary, Weiss, Jessica, primary, Sakashita, Shingo, primary, Zaslaver, Olga, primary, Yu, Man, primary, Caudy, Amy A., primary, St-Pierre, Julie, primary, Hawkins, Cynthia, primary, Kislinger, Thomas, primary, Liu, Geoffrey, primary, Shepherd, Frances A., primary, Tsao, Ming-Sound, primary, and Moran, Michael F., primary

Published
2023
Full Text
View/download PDF

39. Supplementary Data 2 from Mitochondrial Aconitase ACO2 Links Iron Homeostasis with Tumorigenicity in Non–Small Cell Lung Cancer

Author

Mirhadi, Shideh, primary, Zhang, Wen, primary, Pham, Nhu-An, primary, Karimzadeh, Fereshteh, primary, Pintilie, Melania, primary, Tong, Jiefei, primary, Taylor, Paul, primary, Krieger, Jonathan, primary, Pitcher, Bethany, primary, Sykes, Jenna, primary, Wybenga-Groot, Leanne, primary, Fladd, Christopher, primary, Xu, Jing, primary, Wang, Tao, primary, Cabanero, Michael, primary, Li, Ming, primary, Weiss, Jessica, primary, Sakashita, Shingo, primary, Zaslaver, Olga, primary, Yu, Man, primary, Caudy, Amy A., primary, St-Pierre, Julie, primary, Hawkins, Cynthia, primary, Kislinger, Thomas, primary, Liu, Geoffrey, primary, Shepherd, Frances A., primary, Tsao, Ming-Sound, primary, and Moran, Michael F., primary

Published
2023
Full Text
View/download PDF

40. Table S1 from Mitochondrial Aconitase ACO2 Links Iron Homeostasis with Tumorigenicity in Non–Small Cell Lung Cancer

Author

Mirhadi, Shideh, primary, Zhang, Wen, primary, Pham, Nhu-An, primary, Karimzadeh, Fereshteh, primary, Pintilie, Melania, primary, Tong, Jiefei, primary, Taylor, Paul, primary, Krieger, Jonathan, primary, Pitcher, Bethany, primary, Sykes, Jenna, primary, Wybenga-Groot, Leanne, primary, Fladd, Christopher, primary, Xu, Jing, primary, Wang, Tao, primary, Cabanero, Michael, primary, Li, Ming, primary, Weiss, Jessica, primary, Sakashita, Shingo, primary, Zaslaver, Olga, primary, Yu, Man, primary, Caudy, Amy A., primary, St-Pierre, Julie, primary, Hawkins, Cynthia, primary, Kislinger, Thomas, primary, Liu, Geoffrey, primary, Shepherd, Frances A., primary, Tsao, Ming-Sound, primary, and Moran, Michael F., primary

Published
2023
Full Text
View/download PDF

41. Supplementary Data 1 from Mitochondrial Aconitase ACO2 Links Iron Homeostasis with Tumorigenicity in Non–Small Cell Lung Cancer

Author

Mirhadi, Shideh, primary, Zhang, Wen, primary, Pham, Nhu-An, primary, Karimzadeh, Fereshteh, primary, Pintilie, Melania, primary, Tong, Jiefei, primary, Taylor, Paul, primary, Krieger, Jonathan, primary, Pitcher, Bethany, primary, Sykes, Jenna, primary, Wybenga-Groot, Leanne, primary, Fladd, Christopher, primary, Xu, Jing, primary, Wang, Tao, primary, Cabanero, Michael, primary, Li, Ming, primary, Weiss, Jessica, primary, Sakashita, Shingo, primary, Zaslaver, Olga, primary, Yu, Man, primary, Caudy, Amy A., primary, St-Pierre, Julie, primary, Hawkins, Cynthia, primary, Kislinger, Thomas, primary, Liu, Geoffrey, primary, Shepherd, Frances A., primary, Tsao, Ming-Sound, primary, and Moran, Michael F., primary

Published
2023
Full Text
View/download PDF

42. Data from Mitochondrial Aconitase ACO2 Links Iron Homeostasis with Tumorigenicity in Non–Small Cell Lung Cancer

Author

Mirhadi, Shideh, primary, Zhang, Wen, primary, Pham, Nhu-An, primary, Karimzadeh, Fereshteh, primary, Pintilie, Melania, primary, Tong, Jiefei, primary, Taylor, Paul, primary, Krieger, Jonathan, primary, Pitcher, Bethany, primary, Sykes, Jenna, primary, Wybenga-Groot, Leanne, primary, Fladd, Christopher, primary, Xu, Jing, primary, Wang, Tao, primary, Cabanero, Michael, primary, Li, Ming, primary, Weiss, Jessica, primary, Sakashita, Shingo, primary, Zaslaver, Olga, primary, Yu, Man, primary, Caudy, Amy A., primary, St-Pierre, Julie, primary, Hawkins, Cynthia, primary, Kislinger, Thomas, primary, Liu, Geoffrey, primary, Shepherd, Frances A., primary, Tsao, Ming-Sound, primary, and Moran, Michael F., primary

Published
2023
Full Text
View/download PDF

43. Supplementary Figure 1 from Mitochondrial Aconitase ACO2 Links Iron Homeostasis with Tumorigenicity in Non–Small Cell Lung Cancer

Author

Mirhadi, Shideh, primary, Zhang, Wen, primary, Pham, Nhu-An, primary, Karimzadeh, Fereshteh, primary, Pintilie, Melania, primary, Tong, Jiefei, primary, Taylor, Paul, primary, Krieger, Jonathan, primary, Pitcher, Bethany, primary, Sykes, Jenna, primary, Wybenga-Groot, Leanne, primary, Fladd, Christopher, primary, Xu, Jing, primary, Wang, Tao, primary, Cabanero, Michael, primary, Li, Ming, primary, Weiss, Jessica, primary, Sakashita, Shingo, primary, Zaslaver, Olga, primary, Yu, Man, primary, Caudy, Amy A., primary, St-Pierre, Julie, primary, Hawkins, Cynthia, primary, Kislinger, Thomas, primary, Liu, Geoffrey, primary, Shepherd, Frances A., primary, Tsao, Ming-Sound, primary, and Moran, Michael F., primary

Published
2023
Full Text
View/download PDF

44. Supplementary Figure S1 from Integrating RAS Status into Prognostic Signatures for Adenocarcinomas of the Lung

Author

Starmans, Maud HW., primary, Pintilie, Melania, primary, Chan-Seng-Yue, Michelle, primary, Moon, Nathalie C., primary, Haider, Syed, primary, Nguyen, Francis, primary, Lau, Suzanne K., primary, Liu, Ni, primary, Kasprzyk, Arek, primary, Wouters, Bradly G., primary, Der, Sandy D., primary, Shepherd, Frances A., primary, Jurisica, Igor, primary, Penn, Linda Z., primary, Tsao, Ming-Sound, primary, Lambin, Philippe, primary, and Boutros, Paul C., primary

Published
2023
Full Text
View/download PDF

45. Supplementary Materials from Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma

Author

Wu, Licun, primary, Allo, Ghassan, primary, John, Thomas, primary, Li, Ming, primary, Tagawa, Tetsuzo, primary, Opitz, Isabelle, primary, Anraku, Masaki, primary, Yun, Zhihong, primary, Pintilie, Melania, primary, Pitcher, Bethany, primary, Liu, Geoffrey, primary, Feld, Ron, primary, Johnston, Michael R., primary, de Perrot, Marc, primary, and Tsao, Ming-Sound, primary

Published
2023
Full Text
View/download PDF

47. Data from Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma

Author

Wu, Licun, primary, Allo, Ghassan, primary, John, Thomas, primary, Li, Ming, primary, Tagawa, Tetsuzo, primary, Opitz, Isabelle, primary, Anraku, Masaki, primary, Yun, Zhihong, primary, Pintilie, Melania, primary, Pitcher, Bethany, primary, Liu, Geoffrey, primary, Feld, Ron, primary, Johnston, Michael R., primary, de Perrot, Marc, primary, and Tsao, Ming-Sound, primary

Published
2023
Full Text
View/download PDF

48. Supplementary Figure 2 from NKX3.1 Haploinsufficiency Is Prognostic for Prostate Cancer Relapse following Surgery or Image-Guided Radiotherapy

Author

Locke, Jennifer A., primary, Zafarana, Gaetano, primary, Ishkanian, Adrian S., primary, Milosevic, Michael, primary, Thoms, John, primary, Have, Cherry L., primary, Malloff, Chad A., primary, Lam, Wan L., primary, Squire, Jeremy A., primary, Pintilie, Melania, primary, Sykes, Jenna, primary, Ramnarine, Varune Rohan, primary, Meng, Alice, primary, Ahmed, Omer, primary, Jurisica, Igor, primary, van der Kwast, Theo, primary, and Bristow, Robert G., primary

Published
2023
Full Text
View/download PDF

49. Supplementary Figure Legends 1-2, Tables 1-6 from NKX3.1 Haploinsufficiency Is Prognostic for Prostate Cancer Relapse following Surgery or Image-Guided Radiotherapy

Author

Locke, Jennifer A., primary, Zafarana, Gaetano, primary, Ishkanian, Adrian S., primary, Milosevic, Michael, primary, Thoms, John, primary, Have, Cherry L., primary, Malloff, Chad A., primary, Lam, Wan L., primary, Squire, Jeremy A., primary, Pintilie, Melania, primary, Sykes, Jenna, primary, Ramnarine, Varune Rohan, primary, Meng, Alice, primary, Ahmed, Omer, primary, Jurisica, Igor, primary, van der Kwast, Theo, primary, and Bristow, Robert G., primary

Published
2023
Full Text
View/download PDF

50. Supplementary Figure Legends & Tables from Integrating RAS Status into Prognostic Signatures for Adenocarcinomas of the Lung

Author

Starmans, Maud HW., primary, Pintilie, Melania, primary, Chan-Seng-Yue, Michelle, primary, Moon, Nathalie C., primary, Haider, Syed, primary, Nguyen, Francis, primary, Lau, Suzanne K., primary, Liu, Ni, primary, Kasprzyk, Arek, primary, Wouters, Bradly G., primary, Der, Sandy D., primary, Shepherd, Frances A., primary, Jurisica, Igor, primary, Penn, Linda Z., primary, Tsao, Ming-Sound, primary, Lambin, Philippe, primary, and Boutros, Paul C., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results